Dementia : not only Alzheimer&apos;s disease, an eye on frontotemporal dementia by D. Galimberti & E. Scarpini
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                299
ED
IT
O
R
IA
L
Dementia: Not Only Alzheimer’s Disease, 
an Eye on Frontotemporal Dementia
Demência: Mais do que uma Doença de Alzheimer, 
um Olhar sobre a Demência Frontotemporal
1. Neurology Unit. Dept. of Pathophysiology and Transplantation. University of Milan. Fondazione IRCCS Cà Granda. Ospedale Policlinico. Milan. Italy.
Recebido: 25 de Julho de 2012 - Aceite: 26 de Julho de 2013 | Copyright © Ordem dos Médicos 2013
Daniela GALIMBERTI1, Elio SCARPINI1
Acta Med Port 2013 Jul-Aug;26(4):299-300
 The term Frontotemporal Lobar Degeneration (FTLD) 
encompasses three main clinical syndromes: behavioural 
variant Frontotemporal Dementia (bvFTD), Progressive 
Non Fluent Aphasia (PNFA) and Semantic Dementia (SD). 
It represents a common cause of dementia in subjects un-
der 65 years. The age at onset is typically 45-65 years, 
with a mean average in the 50s, and the prevalence, equal 
among men and women, is 10-15 individuals out of 100 
000. bvFTD is the most frequent FTLD phenotype. It is pri-
marily characterised by behavioural changes and progres-
sive deterioration of personality. Throughout the disease, 
patients show a wide spectrum of symptoms, including 
behavioural alterations, such as disinhibition, overeating 
and impulsiveness, and impairment of cognitive functions, 
with relative sparing of memory. Changes in social behav-
iour, loss of empathy and impairment of social insight are 
early and consistent symptoms of bvFTD. In the last few 
years, it has become clearer and clearer that FTLD rep-
resents a challenging diagnosis: quite often it can present 
also with memory impairment, thus resembling Alzheimer’s 
disease, or with a psychiatric illness, when characterized 
by psychosis.1 In this context, the availability of biomarkers, 
i.e. objective measures of an ongoing pathogenic process, 
represents a crucial point for early diagnosis and treatment 
of FTLD. In an elegant update and guide for clinicians, Peli-
cano Paulos and Massano2 carefully described the current 
knowledge about FTLD, including clinical presentation, di-
agnosis, genetics, and pathology. 
 Regarding the diagnosis, new criteria have been 
published for bvFTD,3 and language presentations.4 
Regarding the former, the main feature is the progressive 
deterioration of behaviour and/or cognition by observation 
or history (provided by a knowledgeable informant). If this 
criterion is satisfied, there are three further levels of certainty 
for bvFTD: possible, probable, or definite. ‘Possible’ bvFTD 
requires three out of six clinically discriminating features 
(dishinibition, apathy/inertia, loss of sympathy/empathy, 
perseverative/compulsive behaviours, hyperorality and 
dysexecutive neuropsychological profile). ‘Probable’ bvFTD 
meets the criteria of ‘possible’ bvFTD plus 1) a significant 
functional decline (by caregiver report or evidenced by 
Clinical Dementia Rating Scale of Functional Activities 
Questionnaire score) 2) imaging results consistent with 
bvFTD (frontal and/or anterior temporal atrophy on MRI 
or CT, or frontal and/or anterior temporal hypoperfusion or 
hypometabolism on PET or SPECT). ‘Definite’ bvFTD imply 
the histopathological evidence of FTLD on biopsy or post 
mortem or the presence of a known pathogenic mutation. 
These new criteria have a flexible structure to account for 
the high heterogeneity at initial presentation. 
 The inclusion of genetics in new criteria derives from 
the recent demonstration that about 10% of cases have 
actually a genetic cause, dominantly inherited. Mutations 
in different genes, including Microtubule Associated Protein 
Tau (MAPT), Progranulin (GRN) and chromosome 9 Open 
Reading Frame 72 (C9ORF72), are associated with a 
variety of phenotypes and age at presentation. Notably, 
the presence of the hexanucleotide repeat expansion in 
C9ORF72 is often associated with FTLD with motor neuron 
disease (MND), that is usually observed in about 20% of 
cases.
 The pathology associated with FTLD is intriguing. The 
first histopathological findings were described in 1911 by 
Alois Alzheimer, who observed ballooned neurons containing 
tau protein and argyrophilic intracytoplasmic inclusions. He 
named them ‘Pick cells’ and ‘Pick bodies’, respectively, after 
Arnold Pick, who reported the first case in 1892. Decades 
later, it was observed that these characteristics were absent 
is some Pick disease brains, resulting in the term ‘FTLD 
lacking distinctive histophatology’. A positive staining for 
ubiquitin was shown in these cases and, in 2006, truncated 
and hyperphosphorylated isoforms of the TAR-DNA binding 
protein (TDP)-43 were recognized as main components of 
the ubiquitin-positive inclusions.5 
 Despite these advances in the definition of mechanisms 
at the basis of FTLD, the disease if often unfamiliar to 
citizens and physicians. To fill this gap, in their review, 
Pelicano Paulos and Massano2 give information on the 
clinical management of the disease, including genetic 
counselling for subjects with a positive family history for 
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dementia. 
 The ultimate aim of a better management of FTLD and 
a better understanding of mechanisms at its basis is the 
identification of targets to develop treatments. Considering 
the wide heterogeneity of the pathology, the big future 
challenge will be to identify biomarkers for recognizing 
in life specific changes occurring in the brain, in order to 
develop tailored disease-modifying treatments for different 
pathologies (i.e. inhibitors of tau protein deposition or drugs 
able to restore TDP-43 functioning).
CONFLICT OF INTERESTS
 None stated.
FUNDING SOURCES
 None stated. 
Galimberti D, et al. Dementia: not only alzheimer’s disease, Acta Med Port 2013 Jul-Aug;26(4):299-300
ED
ITO
R
IA
L
REFERENCES
1. Galimberti D, Fenoglio C, Serpente M, Villa C, Bonsi R, Arighi A, et 
al. Autosomal dominant frontotemporal lobar degeneration due to the 
C9ORF72 hexanucleotide repeat expansion: late-onset psychotic 
clinical presentation. Biol Psychiatry. 2013; S0006-3223(13)00130-3. 
2. Pelicano Paulos J, Massano J. Clinical, genetic and neuropathological 
features of frontotemporal dementia: an update and guide. Acta Med 
Port. 2013;26:392-401.
3. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, 
Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the 
behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-
77. 
4. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, 
Cappa SF, et al. Classification of primary progressive aphasia and its 
variants. Neurology. 2011;76:1006-14.
5. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou 
TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration 
and amyotrophic lateral sclerosis. Science. 2006;314:130-3.
